Xiumei Bu

Xiumei Bu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
XGXiuyan Gao
Xiuyan Gao
GXGuangjun Xu
Guangjun Xu
NFNingning Fu
Ningning Fu
QBQi Ben
Qi Ben
LWLin Wang
Lin Wang
XBXiumei Bu
Xiumei Bu
Objectives: This comprehensive review and meta-analysis aimed to thoroughly identify the effectiveness of music therapy (MT) in improving behavioral symptoms in children with autism spectrum disorders (ASD) by analyzing the data from all relevant randomized controlled trials (RCTs) related to this field.Methods: From inception until September 18, 2024, PubMed, Web of Science, the Cochrane Library, SinoMed, and Embase were searched. Two reviewers extracted the data separately, and any controversies between the authors’ assessments were resolved by conversation or speaking with another author. The behavioral symptoms scale score before and after the intervention was taken from the included trials and used to reflect the therapeutic effect of music therapy in children with autism.Results: 2607 records across all retrieved databases were discovered, thirteen of which were included in a meta-analysis with 1160 participants. According to the meta-analysis, children with autism showed a substantial improvement in their behavior symptoms when receiving music treatment (standardized mean difference [SMD] = -0.66, 95% confidence interval [CI]: -0.93 to -0.39, p < 0.001). With I2 = 78% and P < 0.001, we did discover a medium level of heterogeneity among the included studies.Conclusions: MT has a positive impact on improving behavioral symptoms in children with autism. However, given the significant heterogeneity and limitations in this study, RCTs with rigorous methodological quality are still required to confirm the curative benefits of MT in autistic children precisely.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024597939.

18 April 2025 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
XGXiuyan Gao
Xiuyan Gao
GXGuangjun Xu
Guangjun Xu
NFNingning Fu
Ningning Fu
LWLin Wang
Lin Wang
QBQi Ben
Qi Ben
XBXiumei Bu
Xiumei Bu

2 June 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
TZTao Zhang
Tao Zhang
LWLin Wang
Lin Wang
ZRZhetan Ren
Zhetan Ren
RMRu Man
Ru Man
XCXiaozhen Cheng
Xiaozhen Cheng
YYYongduo Yu
Yongduo Yu
Background: Anxiety and depression are highly prevalent among patients with inflammatory bowel disease (IBD) and are closely associated with reduced quality of life and poor treatment adherence. The gut–brain axis has been proposed as a key mechanistic framework, with the gut microbiota playing a central role. However, findings from clinical studies remain inconsistent, and a comprehensive synthesis of the evidence is lacking. Objective: This systematic review aimed to integrate evidence from randomized controlled trials (RCTs) and prospective cohort studies to evaluate the associations between gut microbiota characteristics, microbiota-targeted interventions, and symptoms of anxiety and depression in patients with IBD. Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, EBSCOhost, and Scopus. The search covered records from database inception to October 17, 2025. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A descriptive synthesis approach was used to summarize the findings. Study quality was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Results: Ten studies were included, comprising six prospective cohort studies and four RCTs. These studies included a total of 1,040 patients with IBD. Cohort studies consistently showed that anxiety and depressive symptoms were associated with reduced microbial α-diversity, enrichment of pro-inflammatory taxa, and depletion of short-chain fatty acid (SCFA)-producing bacteria. These associations persisted after adjustment for inflammatory markers. They were also observed when analyses were restricted to patients in remission. This suggests that the associations may not be fully explained by disease activity. Evidence from RCTs showed that microbiota-targeted interventions, including probiotics and fecal microbiota transplantation, modulated microbial composition and reduced anxiety and depression scores. Studies combining psychological interventions with microbiota profiling also suggested potential effects on gut microbial composition. However, the findings remain heterogeneous. Conclusion: Current evidence supports a close and potentially bidirectional association between gut microbiota dysbiosis and anxiety and depression in patients with IBD. Both microbiota-targeted interventions and psychological therapies may represent promising strategies for managing psychological comorbidities in IBD. Future large-scale, standardized longitudinal studies and randomized controlled trials are warranted to clarify directionality, test causal hypotheses, and develop personalized intervention approaches. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251166542.